US29446K1060 - Common Stock
EQUILLIUM INC
NASDAQ:EQ (5/3/2024, 7:00:01 PM)
After market: 1.6601 -0.01 (-0.59%)1.67
+0.11 (+7.05%)
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. Its pipeline consists of novel, first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101 is a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, which is under evaluation in a Phase II clinical study of patients with alopecia areata. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21 and is under evaluation in a Phase I first-in-human clinical study that includes healthy volunteers and celiac disease patients. Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway for the modulation of effector T cells and is under evaluation in a Phase III clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase Ib clinical study of patients with lupus/lupus nephritis.
EQUILLIUM INC
2223 Avenida de La Playa Ste 105
La Jolla CALIFORNIA 92037
P: 18584125302
CEO: Bruce D. Steel
Employees: 45
EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Equillium (NASDAQ:EQ) just reported results for the fourth quarter of 2023.Equi...
Here you can normally see the latest stock twits on EQ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: